Skip to main content

Advertisement

Table 2 Extractable nuclear antigen (ENA) antibody typing for siblings II-1 and II-2 at initial presentation, at relapse of disease and 8 months after ofatumumab

From: Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ

ENA antibody typing Patient II-1 Patient II-2
At presentation At relapse 8 months after ofatumumab At presentation At relapse 8 months after ofatumumab
anti-NRNP negative negative positive negative negative equivocal
anti-SME negative negative positive negative negative positive
anti-Ro negative negative positive negative negative negative
anti-La negative negative negative negative negative negative
anti-Jo-1 negative negative negative negative negative negative
anti-Scl70 negative negative negative negative negative negative
other ENA antibodies weakly positive negative negative weakly positive negative negative